Biodesix, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BDSX research report →
Range $32 – $38
Price Chart
About the company
Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT).
- CEO
- Scott Hutton
- IPO
- 2020
- Employees
- 334
- HQ
- Louisville, CO, US
Get TickerSpark's AI analysis on BDSX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $61.54M
- P/E
- -2.79
- Fwd P/E
- 31.50
- PEG
- -0.04
- P/S
- 0.59
- P/B
- 9.45
- EV/EBITDA
- -7.80
- Div Yield
- 0.00%
- Gross Margin
- 82.36%
- Op Margin
- -18.69%
- Net Margin
- -25.74%
- ROE
- -442.34%
- ROIC
- -24.01%
Latest fiscal year · YoY change
- Revenue
- $88.50M+24.1%
- Gross Profit
- $71.78M+28.8%
- Op Income
- $-27,766,000
- Net Income
- $-35,265,000+17.9%
- EPS
- $-4.67+29.5%
- OCF Growth
- +52.2%
- FCF Growth
- +54.4%
- 52W High
- $31.97
- 52W Low
- $5.26
- 50D MA
- $22.08
- 200D MA
- $18.84
- Beta
- 0.55
- RSI (14)
- 21
- Avg Volume
- 164.58K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Biodesix grew Q3 revenue and volumes, but a sales-force shortfall, primary-care seasonality, and delayed development services projects kept results below plan, leading to a lower full-year guide.· November 5, 2026
- Q3 total revenue rose 10% to $24.0 million, with diagnostic testing revenue up 16% and test volumes up 24%.
- Gross margin stayed strong at 81%, marking the sixth straight quarter above 80%.
- Management said the miss was driven by fewer sales reps than planned, stronger-than-expected primary-care seasonality, and delayed development services project starts.
- Full-year 2026 revenue guidance was cut to $101 million-$103 million, while gross margin is still expected to be about 80%.
- The company highlighted improving October trends, a larger sales force now at about 110 reps, and new clinical/health-system momentum around lung nodule management.
Third-quarter 2026 total revenue was $24.0 million, up 10% from $21.8 million a year ago. Diagnostic testing revenue was $23.0 million, up 16% year over year, while development services revenue was $1.0 million versus $1.9 million last year. Test volumes were approximately 19,400, up 24%, average revenue per test fell 6% year over year due to mix shift toward Nodify CDT, and gross margin was 81%, flat year over year. Operating expenses excluding direct costs and expenses were $25.5 million, up 3% year over year but down 7% sequentially; net loss was $8.0 million, and adjusted EBITDA loss was $3.9 million. The company ended the quarter with $28.4 million in cash and cash equivalents, down $1.6 million from June 30, including $6.3 million of net proceeds from the ATM program. For full-year 2026, Biodesix now expects total revenue of $101 million to $103 million, gross margin of approximately 80%, and continued progress toward profitability.
Scott Hutton said the quarter’s shortfall was largely an execution and timing issue, not a demand or competitive problem. He emphasized that management has already taken corrective action on sales hiring and training, primary-care execution, and development-services timing. Strategically, he pointed to three validation points: the CHEST lung nodule framework, expansion into digital diagnostics with Vanderbilt, and accelerated MRD programs, all of which he said strengthen Biodesix’s long-term position in lung diagnostics. His tone was confident but candid, repeatedly framing Q3 as a temporary setback against a clearer long-term opportunity.
Robin Cowie reported the key numbers: $24.0 million of total revenue, 81% gross margin, $25.5 million of operating expenses excluding direct costs and expenses, $8.0 million net loss, $3.9 million adjusted EBITDA loss, and $28.4 million in cash and cash equivalents. She said average revenue per test declined 6% because of a higher proportion of Nodify CDT tests, partly offset by better reimbursement coverage, and noted that shipping costs rose due to higher fuel costs. She also explained the revised full-year outlook of $101 million-$103 million reflects Q3 results, sales hiring/training timing, and development-services contract execution and revenue recognition. On cash, she noted the quarter included $6.3 million of ATM proceeds.
Analysts focused on why sales-force underperformance and primary-care seasonality hit the quarter so hard, and management said the biggest issue was simply having too few reps in the field, which limited new physician acquisition and pushed teams into maintenance mode. They also asked about the CHEST framework and whether it could accelerate health-system adoption; Scott said it is already creating dialogue, gives CHEST physicians a practical roadmap in the absence of formal guidelines, and supports system-wide onboarding and workflow integration. On guidance, Robin said Q4 development services should look similar to about $1 million, and she later said much of the slipped work is likely to move into 2027.
The company said underlying demand remains strong, with continued physician adoption, stronger October new physician acquisition, and more health-system integrations. Management believes the CHEST framework, smaller-nodule adoption of Nodify CDT, and a larger sales force should support better execution going forward. They also highlighted new adjacent opportunities in digital diagnostics and MRD as longer-term growth drivers.
Results still missed expectations, and management acknowledged that primary-care seasonality and commercial execution were worse than planned. The company’s full-year revenue guide was reduced, and development services timing remains lumpy, with many projects likely slipping into 2027. Revenue per test also declined 6% due to mix shift, which could keep pressure on monetization even as volume grows.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 57.2%
- Shares Outstanding
- 8.14M
- Float Shares
- 4.66M
of shares held by institutions
45 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Aigh Capital Management LLC | 686.02K | ▲ 7.69K |
| Soleus Capital Management, L.P. | 585.96K | ▲ 169.36K |
| Telemark Asset Management, LLC | 539.82K | ▲ 50.00K |
| Aberdeen Group PLC | 287.62K | ▼ 101.02K |
| Vanguard Capital Management LLC | 284.17K | 0 |
| Vanguard Group Inc | 192.14K | ▲ 10.23K |
| Marshall Wace, Llp | 185.69K | ▲ 69.49K |
| Opaleye Management Inc. | 180.00K | ▼ 58.05K |
| Walleye Capital LLC | 124.80K | ▲ 50.36K |
| Perceptive Advisors LLC | 108.69K | ▲ 108.69K |
| Two Sigma Investments, LP | 86.82K | ▲ 41.59K |
| Legato Capital Management LLC | 72.62K | ▼ 8.76K |
Held by 30 ETFs
Biggest fund positions in BDSX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 10, 26 | SCHULER JACK W | buy | 100,000 |
| Sep 30, 26 | PATIENCE JOHN | other | 1,360 |
| Sep 30, 26 | PATIENCE JOHN | other | 1,360 |
| Aug 12, 26 | SCHULER JACK W | buy | 15,000 |
| Aug 11, 26 | SCHULER JACK W | buy | 13,700 |
| Aug 10, 26 | SCHULER JACK W | buy | 13,900 |
| Jun 30, 26 | PATIENCE JOHN | other | 1,361 |
| Jun 30, 26 | PATIENCE JOHN | other | 1,361 |
| Mar 31, 26 | PATIENCE JOHN | other | 1,361 |
| Mar 31, 26 | PATIENCE JOHN | other | 1,361 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BDSX coverage
Recent articles, reports, and earnings notes.
No research on BDSX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BDSX report →BDSX Investors Have Opportunity to Join Biodesix, Inc. Fraud Investigation with SBS Law
businesswire.com · Nov 21
Biodesix (BDSX) Shareholder Alert: Johnson Fistel Investigates Following Sales Force Challenges
globenewswire.com · Nov 20
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodesix, Inc. - BDSX
prnewswire.com · Nov 19
BIODESIX, INC. BDSX INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 57% Share Drop
businesswire.com · Nov 17
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodesix, Inc. - BDSX
globenewswire.com · Nov 17
Biodesix (BDSX) Shares Plunge; Johnson Fistel's Colorado Office Initiates Investigation on Behalf of Investors
globenewswire.com · Nov 16
Biodesix (BDSX) Shares Plunge; Johnson Fistel's Colorado Office Initiates Investigation on Behalf of Investors
globenewswire.com · Nov 11
Biodesix, Inc. (BDSX) Presents at 2026 UBS Global Healthcare Conference Transcript
seekingalpha.com · Nov 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.